These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35786601)

  • 1. Proarrhythmia Risk Assessment Using Electro-Mechanical Window in Human iPS Cell-Derived Cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    Biol Pharm Bull; 2022; 45(7):940-947. PubMed ID: 35786601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
    J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
    da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ
    Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs.
    Wei F; Pence L; Woodling K; Bagam P; Beger R; Gamboa da Costa G; Pang L
    Toxicol Sci; 2022 Jun; 188(1):48-61. PubMed ID: 35478258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
    Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
    Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
    Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
    Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive
    Yoon SH; Lee HL; Jeong DU; Lim KM; Park SJ; Kim KS
    Front Pharmacol; 2023; 14():1220796. PubMed ID: 37649890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-Related Differences in Drug-Induced QT Prolongation and Torsades de Pointes: A New Model System with Human iPSC-CMs.
    Huo J; Wei F; Cai C; Lyn-Cook B; Pang L
    Toxicol Sci; 2019 Feb; 167(2):360-374. PubMed ID: 30247688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
    Ando H; Yoshinaga T; Yamamoto W; Asakura K; Uda T; Taniguchi T; Ojima A; Shinkyo R; Kikuchi K; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
    J Pharmacol Toxicol Methods; 2017; 84():111-127. PubMed ID: 27956204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
    Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
    SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging Model for Analyzing Drug-Induced Proarrhythmia Risks Using Cardiomyocytes Differentiated from Progeria-Patient-Derived Induced Pluripotent Stem Cells.
    Daily N; Elson J; Wakatsuki T
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes.
    Yamazaki D; Kitaguchi T; Ishimura M; Taniguchi T; Yamanishi A; Saji D; Takahashi E; Oguchi M; Moriyama Y; Maeda S; Miyamoto K; Morimura K; Ohnaka H; Tashibu H; Sekino Y; Miyamoto N; Kanda Y
    J Pharmacol Sci; 2018 Apr; 136(4):249-256. PubMed ID: 29555184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.